Vestmark Advisory Solutions Inc. Has $2.86 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Vestmark Advisory Solutions Inc. reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,629 shares of the company’s stock after selling 1,788 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Novo Nordisk A/S were worth $2,858,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NVO. Legacy Financial Advisors Inc. boosted its holdings in shares of Novo Nordisk A/S by 13.1% during the fourth quarter. Legacy Financial Advisors Inc. now owns 12,025 shares of the company’s stock worth $1,244,000 after purchasing an additional 1,393 shares during the period. Sapient Capital LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $65,340,000. Axxcess Wealth Management LLC grew its holdings in shares of Novo Nordisk A/S by 12.3% during the 4th quarter. Axxcess Wealth Management LLC now owns 31,009 shares of the company’s stock valued at $3,208,000 after acquiring an additional 3,407 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its stake in shares of Novo Nordisk A/S by 0.6% in the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after acquiring an additional 90 shares during the last quarter. Finally, Merit Financial Group LLC raised its holdings in shares of Novo Nordisk A/S by 68.1% during the fourth quarter. Merit Financial Group LLC now owns 7,407 shares of the company’s stock worth $766,000 after acquiring an additional 3,002 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NVO shares. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $0.97 on Friday, reaching $123.05. The stock had a trading volume of 5,932,926 shares, compared to its average volume of 3,905,318. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The business’s 50-day moving average price is $127.20 and its two-hundred day moving average price is $112.93. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The stock has a market cap of $552.19 billion, a P/E ratio of 42.43, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. The company had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.